Invention Grant
- Patent Title: Use of equol for treating skin diseases
- Patent Title (中): 使用牛尿酚治疗皮肤病
-
Application No.: US12533169Application Date: 2009-07-31
-
Publication No.: US08668914B2Publication Date: 2014-03-11
- Inventor: Edwin Douglas Lephart , Trent D. Lund , Kenneth David Reginald Setchell , Robert J. Handa
- Applicant: Edwin Douglas Lephart , Trent D. Lund , Kenneth David Reginald Setchell , Robert J. Handa
- Applicant Address: US UT Provo US CO Fort Collins US OH Cincinnati
- Assignee: Brigham Young University,Colorado State University Research Foundation,Children's Hospital Medical Center
- Current Assignee: Brigham Young University,Colorado State University Research Foundation,Children's Hospital Medical Center
- Current Assignee Address: US UT Provo US CO Fort Collins US OH Cincinnati
- Agency: Brinks Gilson & Lione
- Main IPC: A61K8/02
- IPC: A61K8/02 ; A01N43/16

Abstract:
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.
Public/Granted literature
- US20100076071A1 USE OF EQUOL FOR TREATING SKIN DISEASES Public/Granted day:2010-03-25
Information query